Argenx: Strong Vyvgart Execution, Deep Pipeline, and Vision 2030 Drive Compelling Buy-Rated Upside

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Argenx Se yesterday and set a price target of $1,006.00.

Tazeen Ahmad has given his Buy rating due to a combination of factors tied to Argenx’s strong commercial execution and robust growth outlook. He points to Vyvgart’s better-than-expected quarterly sales and the growing global patient base as evidence that the current franchise is scaling effectively, with management signaling continued solid performance into 2026. In his view, the company’s Vision 2030 plan, which targets a much larger treated population and a broader label, underscores meaningful room for further revenue expansion.
Ahmad also emphasizes the breadth and depth of Argenx’s late-stage pipeline as a key driver of future value. Multiple upcoming phase 3 readouts for Vyvgart in additional autoimmune indications, the planned launch of a subcutaneous autoinjector formulation, and a substantial set of earlier-stage studies collectively provide numerous opportunities to widen the product’s commercial footprint. Beyond Vyvgart, he highlights empasiprubart and other immunology assets as potential new pillars of growth, while valuation work (including an updated DCF and improving future EBITDA multiples) supports a price objective that offers material upside from current levels. In combination, these factors support his conviction that Argenx remains a top pick with an attractive risk‑reward profile.

In another report released today, TipRanks – Anthropic also reiterated a Buy rating on the stock with a $883.00 price target.